SEC Form EFFECT filed by Lakewood-Amedex Biotherapeutics Inc.
$LABT
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 13, 2026 4:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 13, 2026 4:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Patent portfolio now includes 71 granted patents and 28 pending patent applications, covering composition of matter, formulation, and use patentsSARASOTA, Fla., May 27, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced an expansion of its global intellectual property portfolio with the issuance of two patents, one each in Australia and New Zealand respectively.
Key formulation, delivery and manufacturing steps completed in preparation for planned Phase 2 clinical trial SARASOTA, Fla., May 18, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced positive data for its lead compound, Nu-3, as it advances towards a Phase 2 trial. Nu-3 is being developed as a topically delivered treatment for mildly infected diabetic foot ulcers (iDFU) designed to reduce the risk of antimicrobial resistance (AMR).
Specialized CRO partnership supports Phase 2 program to advance Nu-3 toward potential registration pathway in large, underserved iDFU marketSARASOTA, Fla., May 12, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for locally treatable infectious diseases called the Bisphosphocin® class, today announced that it has entered into an agreement with Professional Education and Research Institute LLC (PERI) to serve as the contract research organization (CRO) for its upcoming Phase 2 clinical program of Nu-3, the Company's lead Bisphosphocin® product for the
4 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Issuer)
3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Issuer)
3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Issuer)
424B3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)
424B3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)
10-Q - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)
Appointment strengthens Board with seasoned public company biotech executive following recent Nasdaq direct listingSARASOTA, Fla., April 28, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the appointment of Joseph Tucker, Ph.D., Chief Executive Officer of Enveric Biosciences (NASDAQ:ENVB), to its Board of Directors. Dr. Tucker's appointment follows Lakewood-Amedex Biotherapeutics' recent direct listing on Nasdaq and represents a key step in strengthening the Company's governance